Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28018145 | 0.83 | NOTUM (0.39) | NOTUMTP53GRM8GRM4SCN8A | |
| SCHEMBL24253389 | 0.83 | GRM8 (0.42) | NOTUMGRM8GRM4FKBP5CRBN | |
| SCHEMBL19441070 | 0.83 | NOTUM (0.39) | NOTUMTP53GRM8GRM4SCN8A | |
| SCHEMBL28265713 | 0.82 | HDAC6 (0.45) | NOTUMTP53GRM8GRM4SCN8A | |
| SCHEMBL19365913 | 0.79 | HDAC4 (0.46) | NOTUMHDAC4HDAC8HPGDALDH1A1 | |
| SCHEMBL18650816 | 0.79 | NOTUM (0.59) | NOTUMTYRHDAC4HDAC8HPGD | |
| SCHEMBL22151411 | 0.78 | NOTUM (0.58) | NOTUMCYP3A4SCN8ASCN10AHDAC6 | |
| SCHEMBL18474686 | 0.77 | GRM8 (0.39) | NOTUMHDAC4HDAC8CA2SMN1; SMN2 | |
| SCHEMBL24826394 | 0.74 | LMNA (0.37) | TYRHDAC4HDAC8HPGDALDH1A1 | |
| SCHEMBL27377916 | 0.74 | NOTUM (0.37) | NOTUMGRM8GRM4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090221597-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-03 | — | — | US | disclosed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20090062261-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7217712-B2 | 4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | NOTUM 4482/4885TYR 4826/4885HDAC4 3120/4885 |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | NOTUM 3220/4885TYR 3724/4885HDAC4 1569/4885 |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | NOTUM 819/4885TYR 3083/4885HDAC4 899/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | NOTUM 2689/4885TYR 1118/4885HDAC4 2732/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | NOTUM 2628/4885TYR 470/4885HDAC4 1486/4885 |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3CD | NOTUM 3154/4885TYR 1377/4885HDAC4 2450/4885 |
| US-20090062261-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | NR4A1, NR0B2, NR0B1 | NOTUM 3462/4885TYR 2935/4885HDAC4 309/4885 |
| US-20080132507-A1 | Hydrazide Derivatives | H1-10, H1-4, H1-3 | NOTUM 4107/4885TYR 1087/4885HDAC4 36/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | NOTUM 2348/4885TYR 2305/4885HDAC4 1909/4885 |
| US-20090221597-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCD3 | NOTUM 3928/4885TYR 4803/4885HDAC4 2800/4885 |
| US-20080207609-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | NOTUM 3146/4885TYR 1348/4885HDAC4 2654/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | NOTUM 4281/4885TYR 981/4885HDAC4 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.